- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
January 19th, 2005
Melbourne pharmaceutical developer Starpharma Holdings is on the verge of signing a strategic deal with Dow Chemical Company that would shore up its intellectual property position and give it access to an estimated 200 patents in the competitive field of nanotechnology.
The deal, which could be finalised by the end of next week, is expected to involve the transfer of Dow's extensive intellectual property portfolio into Starpharma's subsidiary Dendritic Nanotechnologies (DNT). In return, Dow will receive a 31 per cent equity stake in DNT.
|Related News Press|
Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016
Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016
Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016
Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016
Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016
Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016
NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016